AUTHOR=Bohbot Yohann , Tordjman Léa , Dreyfus Julien , Le Tourneau Thierry , Lavie-Badie Yoan , Selton-Suty Christine , Elegamandji Benjamin , L’official Guillaume , Fraix Antoine , Aghezzaf Samy , Turgeon Pierre Yves , Messika Zeitoun David , Enriquez-Sarano Maurice , Coisne Augustin , Donal Erwan , Tribouilloy Christophe 

TITLE=Comparison of effective regurgitant orifice area by the PISA method and tricuspid coaptation gap measurement to identify very severe tricuspid regurgitation and stratify mortality risk

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1090572

DOI=10.3389/fcvm.2023.1090572

ISSN=2297-055X

ABSTRACT=<sec><title>Introduction</title><p>Various definitions of very severe (VS) tricuspid regurgitation (TR) have been proposed based on the effective regurgitant orifice area (EROA) or tricuspid coaptation gap (TCG). Because of the inherent limitations associated with the EROA, we hypothesized that the TCG would be more suitable for defining VSTR and predicting outcomes.</p></sec><sec><title>Materials and methods</title><p>In this French multicentre retrospective study, we included 606 patients with ≥moderate-to-severe isolated functional TR (without structural valve disease or an overt cardiac cause) according to the recommendations of the European Association of Cardiovascular Imaging. Patients were further stratified into VSTR according to the EROA (≥60 mm<sup>2</sup>) and then according to the TCG (≥10 mm). The primary endpoint was all-cause mortality and the secondary endpoint was cardiovascular mortality.</p></sec><sec><title>Results</title><p>The relationship between the EROA and TCG was poor (<italic>R</italic><sup>2 </sup>=<sup> </sup>0.22), especially when the size of the defect was large. Four-year survival was comparable between patients with an EROA &lt;60 mm<sup>2</sup> vs. ≥60 mm<sup>2</sup> (68 ± 3% vs. 64 ± 5%, <italic>p</italic> = 0.89). A TCG ≥10 mm was associated with lower four-year survival than a TCG &lt;10 mm (53 ± 7% vs. 69 ± 3%, <italic>p</italic> &lt; 0.001). After adjustment for covariates, including comorbidity, symptoms, dose of diuretics, and right ventricular dilatation and dysfunction, a TCG ≥10 mm remained independently associated with higher all-cause mortality (adjusted HR[95% CI] = 1.47[1.13–2.21], <italic>p</italic> = 0.019) and cardiovascular mortality (adjusted HR[95% CI] = 2.12[1.33–3.25], <italic>p</italic> = 0.001), whereas an EROA ≥60 mm<sup>2</sup> was not associated with all-cause or cardiovascular mortality (adjusted HR[95% CI]: 1.16[0.81–1.64], <italic>p</italic> = 0.416, and adjusted HR[95% CI]: 1.07[0.68–1.68], <italic>p</italic> = 0.784, respectively)</p></sec><sec><title>Conclusion</title><p>The correlation between the TCG and EROA is weak and decreases with increasing defect size. A TCG ≥10 mm is associated with increased all-cause and cardiovascular mortality and should be used to define VSTR in isolated significant functional TR.</p></sec>